These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 31879362)

  • 61. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
    Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
    Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
    Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D
    J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.
    McCracken MN; Cha AC; Weissman IL
    Clin Cancer Res; 2015 Aug; 21(16):3597-601. PubMed ID: 26116271
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
    Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
    Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
    Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
    Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair.
    Gao J; Pang Z; Wang Q; Tan Y; Li Q; Tan H; Chen J; Yakufu W; Wang Z; Yang H; Zhang J; Sun D; Weng X; Wang Q; Qian J; Song Y; Huang Z; Ge J
    Adv Sci (Weinh); 2024 Jun; 11(24):e2306388. PubMed ID: 38477522
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
    Li Y; Liu J; Chen W; Wang W; Yang F; Liu X; Sheng Y; Du K; He M; Lyu X; Li H; Zhao L; Wei Z; Wang F; Zheng S; Sui J
    J Hematol Oncol; 2023 Jan; 16(1):2. PubMed ID: 36650558
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer.
    Tan Y; Chen H; Zhang J; Cai L; Jin S; Song D; Yang T; Guo Z; Wang X
    Eur J Med Chem; 2022 Feb; 229():114047. PubMed ID: 34915428
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
    Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
    Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
    Hao Y; Zhou X; Li Y; Li B; Cheng L
    Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.
    Tang Z; Zhong MC; Qian J; Galindo CC; Davidson D; Li J; Zhao Y; Hui E; Veillette A
    Nat Immunol; 2023 Dec; 24(12):2032-2041. PubMed ID: 37945822
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
    Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 80. Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies.
    Chan H; Trout CV; Mikolon D; Adams P; Guzman R; Mavrommatis K; Abbasian M; Hadjivassiliou H; Dearth L; Fox BA; Sivakumar P; Cho H; Hariharan K
    Cancer Res Commun; 2024 Feb; 4(2):505-515. PubMed ID: 38319147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.